Orchestra BioMed Showcases AVIM Therapy at HRS 2025 Annual Meeting
The Heart Rhythm Society (HRS) 2025 Annual Meeting will witness a significant event as Orchestra BioMed Holdings, Inc. prepares to host a satellite symposium focused on its groundbreaking atrioventricular interval modulation (AVIM) therapy. This innovative approach aims to tackle uncontrolled hypertension, a major health risk affecting millions.
Advancements in Hypertension Management
With the FDA recently granting Breakthrough Device Designation to AVIM therapy, the impending symposium highlights the urgency and innovation in hypertension management. This designation is vital for patients suffering from uncontrolled hypertension, particularly those at increased cardiovascular risk. During the symposium, experts will delve into the mechanism of action of AVIM therapy and the existing clinical evidence supporting its effectiveness.
Lead Presenters and Critical Topics
On April 25, 2025, at the Hilton San Diego Bayfront Hotel, industry leaders in the fields of electrophysiology and heart failure will gather at the symposium titled “The Future of Cardiac Pacing: Unlocking the Potential of Atrioventricular Interval Modulation (AVIM) Therapy.” The session aims to address the unmet needs of hypertension management and showcase the impressive clinical results derived from earlier studies.
Supporting Research and Collaboration
Evidence presented from the MODERATO I and II studies will demonstrate how AVIM therapy has effectively lowered systolic blood pressure, with significant improvements noted in cardiac functions. The collaboration between Orchestra BioMed and Medtronic, plc enhances the scope of research, especially with the BACKBEAT global pivotal study currently enrolling participants.
The Impact of AVIM Therapy
AVIM therapy represents a paradigm shift in managing hypertension. The therapy, utilizing an implantable system that functions through conduction system pacing, aims to substantially lower blood pressure for patients who remain resistant despite traditional treatment options. Preliminary studies have impressed clinicians, indicating the potential for consistent blood pressure reductions.
Exploring Future Opportunities
As the symposium unfolds, informative presentations by notable figureheads such as Dr. Vivek Reddy from Mount Sinai Hospital will address both the current landscape of hypertension treatment and the expected changes that AVIM may bring. Discussions around the BACKBEAT pivotal study's rationale will further solidify the goal of positioning AVIM therapy among leading hypertension solutions.
About Orchestra BioMed and Its Mission
Orchestra BioMed (NASDAQ: OBIO) is committed to developing high-impact medical technologies aimed at changing patient outcomes through innovative treatments. With strategic partnerships enabled by their collaborative business model, Orchestra BioMed focuses on advancing products like AVIM therapy and the Virtue Sirolimus AngioInfusion Balloon for treating artery diseases.
Investor and Media Relations
For questions or additional information, interested parties may contact investor relations via Jeremy Feffer at LifeSci Advisors or reach out to Kelsey Kirk-Ellis for media inquiries within Orchestra BioMed.
Frequently Asked Questions
What is the purpose of the AVIM therapy symposium at HRS 2025?
The symposium aims to showcase the advancements in AVIM therapy for managing hypertension, discussing its mechanisms, clinical evidence, and future implications.
Who are the main presenters at the symposium?
Leading experts such as Dr. Vivek Reddy will present critical insights into AVIM therapy and its impact on patient care.
What was the significance of the FDA Breakthrough Device Designation?
The designation highlights the urgent need for effective treatments for uncontrolled hypertension, enabling faster regulatory pathways for AVIM therapy.
How does AVIM therapy differ from conventional treatments?
AVIM therapy aims to address patients resistant to traditional treatments, focusing on long-term blood pressure reduction through unique pacing methods.
What future studies is Orchestra BioMed pursuing in relation to AVIM therapy?
Orchestra BioMed is enrolling patients in the BACKBEAT global pivotal study to assess the safety and efficacy of AVIM therapy further.
